Skip to main content
SpringerLink
Log in

Wirksamkeit eines Sabal-Urtica-Kombinationspräparats bei der Behandlung der benignen Prostatahyperplasie (BPH)

Eine doppelblinde placebokontrollierte Langzeitstudie

  • Published:
Der Urologe B

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Sökeland J (1993) Urologie, 11. Aufl. Thieme, Stuttgart, S 255–256

    Google Scholar 

  2. Roos NP, Wennberg JE, Malenka DJ et al. (1989) Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyper-plasia. N Engl J Med 320: 1120–1124

    Article  CAS  PubMed  Google Scholar 

  3. Doll HA, Black NA, McPherson K et al. (1992) Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol 147: 1566–1573

    CAS  PubMed  Google Scholar 

  4. Sultan C, Terraza A, Devillier C et al. (1984) Inhibition of androgen metabolism and binding by a liposterolic extract of „Serenoa repens B” in human foreskin fibroblasts. J Steroid Biochem 20: 515–519

    Article  CAS  PubMed  Google Scholar 

  5. Düker EM, Kopanski L, Schweikert HU (1989) Inhibition of 5α-reductase activity by extracts from Sabal serrulata. Planta Med 55: 587

    Article  Google Scholar 

  6. Kraus R, Spiteller G, Bartsch W (1991) (10E, 12Z)-9-Hydroxy 10, 12-octadeca-diensäure, ein Aromatase-Hemmstoff aus dem Wurzelextrakt von Urtica dioica. Liebigs Ann Chem 4: 335–339

    Article  Google Scholar 

  7. Breu W, Stadler F, Hagenlocher M, Wagner H (1992) Der Sabalfrucht-Extrakt SG 291. Ein Phytotherapeutikum zur Behandlung der benignen Prostatahyperplasie. Z Phytother 13: 107–115

    Google Scholar 

  8. Koch E, Biber A (1994) Pharmakologische Wirkungen von Sabal- und Urtika-extrakten als Grundlage für eine rationale medikamentöse Therapie der benignen Prostatahyperplasie. Urologe B 34: 90–95

    Google Scholar 

  9. Le Moal MA, Truffa-Bachi P (1988) Urtica dioica agglutinin, a new mitogen for murine T lymphocytes: unaltered interleukin-1 production but late interleukin-2-mediated proliferation. Cell Immunol 115: 24–35

    Article  Google Scholar 

  10. Hiermann A (1989) Über Inhaltsstoffe von Sabalfrüchten und deren Prüfung auf entzündungshemmende Wirkung. Arch Pharm 322: 111–114

    Article  CAS  Google Scholar 

  11. Wagner H, Wilier F (1990) Chemie und Pharmakologie von Urticapräparaten. Chemie und Pharmakologie von Urticapräparaten. Nat Ganzheitsmed 3: 309–312

    Google Scholar 

  12. Breu W, Hagenlocher M, Redl K et al. (1992) Antiphlogistische Wirkung eines mit hyperkritischem Kohlendioxid gewonnenen Sabalfrucht-Extraktes. Arzneim Forsch/Drug Res 42: 547–551

    CAS  Google Scholar 

  13. Otto U, Wagner B, Becker H et al. (1992) Transplantation of human benign hyperplastic prostate tissue into nude mice: First results of systemic therapy. Urol Int 48: 167–170

    Article  CAS  PubMed  Google Scholar 

  14. Schulze H, Berges R, Paschold K, Senge T (1992) Neue konservative Therapieansätze bei der benignen Prostatahyperplasie. Urologe A 31: 8–13

    Google Scholar 

  15. Cockett ATK, Aso Y, Denis L et al. (eds) (1991) The international consultation on benign prostatic hyperplasia (BPH). SCI Paris

  16. Cockett ATK, Khoury S, Aso Y et al. (eds) (1993) The 2nd international consultation on benign prostatic hyperplasia (BPH). SCI Paris

  17. Schneider H-J, Honold E, Masuhr T (1995) Behandlung der benignen Prostatahyperplasie. Fortschr Med 113: 25–28

    Google Scholar 

  18. Jorgensen IB, Jensen KM, Bille-Brahe NE et al. (1986) Uroflowmetry in asymptomatic elderly males. Br J Urol 58: 390–395

    Article  CAS  PubMed  Google Scholar 

  19. Anonym (1991) Symptom-bezogener Index der AUA für das Prostataadenom. DGU-Mitteilungen 3: 109–110

    Google Scholar 

  20. Barry MJ, Fowler FJ, O’Leary MP et al. (1992) The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148: 1549–1557

    CAS  PubMed  Google Scholar 

  21. Zwergel T, Zwergel U (1993) Benigne Prostataerkrankungen — Differentialdiagnostik und -therapie. Urologe A 32: 67–80

    Google Scholar 

  22. Hunter DJW, McKnee CM, Sanderson CFB, Black NA (1994) Appropriate indications for prostatectomy in the UK — results of a consensus panel. J Epidemiol Community Health 48: 58–64

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Wasson JH, Reda DJ, Bruskewitz RC et al. (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 332: 75–79

    Article  CAS  PubMed  Google Scholar 

  24. Berges RR, Windeier J, Trampisch HJ, Senge T (1995) Randomisierte plazebo-kontrollierte klinische Doppelblindstudie von ß-Sitosterin bei Patienten mit symptomatischer benigner Prostatahyperplasie. Lancet 345: 29–32

    Article  Google Scholar 

  25. Gormley GJ, Stoner E, Bruskewitz RG et al. (1992) The effect of Finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185–1191

    Article  CAS  PubMed  Google Scholar 

  26. The Finasteride Study Group (1993) Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22: 291–299

    Article  Google Scholar 

  27. Hohne JB, Christensen MM, Rasmussen PCh et al. (1994) 29-week Doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol 28: 77–82

    Article  Google Scholar 

  28. Kirby RS, Coppinger SWC, Corcoran MO et al. (1987) Prazosin in the treatment of prostatic obstruction. Brit J Urol 60: 136–142

    Article  CAS  PubMed  Google Scholar 

  29. Mattei FM, Capone M, Acconcia A (1988) Impiego dell’estratto di Serenoa repens nel trattamento medico della ipertrofia prostatica benigna. Urologia 55: 547–552

    Google Scholar 

  30. Romics I, Schmitz H, Frang D (1993) Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. Int Urol Nephrol 25: 565–569

    CAS  PubMed  Google Scholar 

  31. Bach D, Ebeling L (1993) Langzeitbehandlung der BPH mit Sabalextrakt. Therapiewoche 43: 2212–2216

    Google Scholar 

  32. Braeckman J (1994) The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study. Cur Ther Res 55: 776–785

    Article  Google Scholar 

  33. Dathe G, Schmidt H (1987) Phytotherapie der benignen Prostatahyperplasie. Doppelbhndstudie mit Extractum Radicis urticae (ERU). Urologe [B] 27: 223–226

    Google Scholar 

  34. CPMP Working party on efficacy of medicinal products (1990) Note for guidance: Good clinical practice for trials on medicinal products in the European Community. Pharm Ind 52: 1476–1485

    Google Scholar 

  35. Mc Connell JD (1994) Why pressure-flow studies should be optional and not mandatory studies for evaluating men with benign prostatic hyperplasia. Urology 44: 156–158

    Article  Google Scholar 

  36. Barry MJ, Fowler FJ, O’Leary MP et al. (1992) Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. J Urol 148: 1558–1563

    CAS  PubMed  Google Scholar 

  37. O’Leary MP, Barry MJ, Fowler FJ (1992) Hard measures of subjective outcomes: Validating symptom indexes in urology. J Urol 148: 1546–1548

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arzt für Urologie, Karlstraße 13, D-76133, Karlsruhe

    H. Metzker

  2. Klinische Forschung, Dr. Willmar Schwabe Arzneimittel, Karlsruhe

    M. Kieser & U. Hölscher

Authors
  1. H. Metzker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Hölscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Metzker, H., Kieser, M. & Hölscher, U. Wirksamkeit eines Sabal-Urtica-Kombinationspräparats bei der Behandlung der benignen Prostatahyperplasie (BPH). Der Urologe B 36, 292–300 (1996). https://doi.org/10.1007/s001310050033

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s001310050033

Search

Navigation